Targeting the NRF2/GPX4 axis sensitizes cancer cells to ferroptosis and improves therapy efficacy, as seen with sorafenib in hepatocellular carcinoma and oxaliplatin in colorectal cancer[62,89]. Here, NFE2L2 is linked to colorectal cancer.